MiGenTra GmbH
Bertrand Chol is an experienced professional in the field of biotechnology and biopharmaceuticals, currently serving as the Head of R&D Bioprocess Development and GMP Production at MiGenTra GmbH since October 2022. Chol has a robust background in managing CMC development programs for biosimilar products, including monoclonal antibodies and CAR T cell therapies. Previous roles include serving as Deputy CEO (Intern) at Grapheal, guiding strategic marketing efforts, and as Biotechnological Process Development and Production Manager at Pierre Fabre, overseeing GMP biomanufacturing operations. Early career experience includes bioprocess development at PX'Therapeutics, research engineering at Merck KGaA, and vaccine manufacturing process validation at Sanofi Pasteur. Education includes a Master of Engineering in biotechnology from Polytech Clermont, an MBA from Grenoble IAE, and ongoing Executive MBA studies.
This person is not in any teams
This person is not in any offices
MiGenTra GmbH
MiGenTra is a healthcare transforming medicines company, and a subsidiary of ProBioGen, with a focus on high quality medicines at affordable prices. The company allows for product development in the field of Biosimilars, Cell and Gene Therapies and vaccines especially for Egypt, the Middle East and Africa, and will therefore provide access to key healthcare transforming medicines, while strengthening regional and local manufacturing capacity in the region. MiGenTra combines scientific and manufacturing subject matter expertise from both contributing companies, ProBioGen and Minapharm Pharmaceuticals and is headquartered in Berlin, Germany and has access to a site in Cairo, Egypt, where the main manufacturing plant is located.